$3.55
0.030.85%
Last update: Nov 11, 9:30 AM
Verrica Pharmaceuticals Inc
VRCANASDAQ
Verrica Pharmaceuticals fell 3.8% from $3.66 to $3.52, behind the S&P 500's +9.8%. Its worst day was Dec 3 (−17.8%), and its low came Nov 5 at $3.09.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.13 beat the $-0.97 estimate on $14.3M revenue (est. $12.7M).
+1.6% · S&P 500 0.0%
Verrica Pharmaceuticals closed at its highest level of the year, 148.6% above where the year started.
Story events cover the past 12 months · Times ET
+35.6%, the year's best day, on 3M shares, the year's heaviest volume · S&P 500 +0.5%
EPS of $-0.51 beat the $-0.56 estimate on $5.1M revenue (est. $4.4M).
+4.7% · S&P 500 −0.1%
EPS of $-0.41 beat the $-0.59 estimate on $5.0M revenue (est. $4.6M).
+3.1% · S&P 500 +0.6%
EPS of $-0.48 beat the $-0.48 estimate on $5.9M revenue (est. $5.9M).
−5.2% · S&P 500 +0.6%
Verrica Pharmaceuticals closed at its lowest level of the year, 15.6% below where the year started.
−10.6% · S&P 500 −4.4%
Where it ended: a close of $3.52 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 12, 2026 (EPS est. $-0.49, revenue est. $6.2M).
Nothing in the past 12 months.
All VRCA dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for VRCA and SPY from Benzinga historical bars. Not investment advice.
